Found 20 articles
Novigenix Announces Discovery of Liquid Biopsy Immunotherapy Response Biomarkers in Metastatic Melanoma
Novigenix SA, a leading Swiss biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions announced discovery of new Immuno-Transcriptomic signatures for prediction of response to immunotherapy and patient monitoring in metastatic melanoma.
Colorectal Cancer Market Size, Competitors Strategy, Regional Analysis and Industry Growth by Forecast to 2026
The industry analysis report is considered a valuable source of information about the global Colorectal Cancer industry and lays stress on the future market scope, emerging industry trends, industry statistics, and market growth potential during the forecast years.
With the Thanksgiving holiday upon us, BioSpace felt it was important to give thanks for some of the positive things that have happened this year. And there are many!
mRNA has built its reputation as a type of vaccine to fight COVID-19, but its capabilities extend beyond vaccines into therapeutics and even diagnostics.
According to The Insight Partners market research titled 'Colorectal Cancer to 2027 – Global Analysis and Forecasts by Modality, and End User'.
The market for colorectal cancer drugs is driven by frequent diagnostic tests and drug launches.
Colorectal Cancer Diagnosis and Therapeutics Market Capital Expenditure, SWOT Analysis till 2029 | Abbott, Beckman Coulter, Clinical Genomics
New York City, NY: April 08, 2020 – Published: The demand in the global colorectal cancer diagnosis and therapeutics market is expected to increment at a healthy CAGR during the forecast period of 2020 to 2029, gaining traction from a number of factors such as rising percentage of geriatrics in the world population, the prevalence of target diseases, growing demand for early detection of incurable diseases, and the presentation of innovative applications. On the other hand, the absence of a pre
Novigenix-Led Consortium Secures Eurostars Funding to Develop Multi-Omics Test for Colon Cancer Detection and Monitoring
Total amount up to €1 million awarded to consortium of leading cancer centers and innovative healthcare companies
Novigenix Develops New NGS-based Immune Cell Type Specific RNA Signatures for Early Colon Cancer Detection
Immune cell type specific profiles correlate with traditional blood cell count method
Global In-vitro Colorectal Cancer Screening Tests Market 2019-2023 | Evolving Opportunities with Abbott & Danaher | Technavio
Technavio has announced its latest market research report titled global in-vitro colorectal cancer screening tests market 2019-2023.
Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes solutions for early cancer detection and precision medicine, announced a collaboration agreement with RadioMedix Inc., a radiopharmaceutical company, to develop a precision diagnostic test based on Novigenix’s technology.
First liquid biopsy test reimbursed in Switzerland for colon cancer screening through private outpatient supplementary insurance product offered by Helsana
Novigenix SA announced promising data from a study of a new Immuno-Transcriptomic signature for early detection of colorectal cancer (CRC) in blood.
Novigenix and BioLizard Sign Collaboration Agreement for Development of NGS Based Diagnostic Algorithm
Novigenix SA announced a collaboration agreement with BioLizard, an innovative bioinformatics company that aims to solve the most challenging questions in biology.
Novigenix to Present Data on New Molecular Signature for Early Detection of Colon Cancer at ESMO 2019
Novigenix SA announced the discovery of a new molecular signature in blood that can be used for early colorectal cancer detection using its new LITOseek™ platform.
Novigenix SA announced the appointment of Francois Martelet, M.D., to its Board of Directors as a non-executive director.
Novigenix Appoints Dr. Jan Groen as CEO to Lead Expansion to Multi-Product Cancer Diagnostic Platform Company
ImmunoTranscriptomic platform combines identification of immune cell mRNA signatures with AI for early cancer detection
Novigenix Signs Distribution Agreement With Dr Risch Medical Laboratory To Access Swiss German Market For Colox, Its Blood Based Colorectal Cancer Test
Novigenix Acquires Blood-Based Molecular Diagnostics Test Colox® And Prepares Its Further Commercial Rollout In Switzerland And Europe To Improve The Early Detection Of Colorectal Cancer